MBX Biosciences' (MBX) hypoparathyroidism drug, canvuparatide, is a "key catalyst" for the company as its potentially favorable efficacy to current treatments could be a $2 billion global peak sales opportunity, said Oppenheimer said in a Wednesday note.
Oppenheimer said its enthusiasm for MBX Biosciences stems from the company's precision endocrine peptide platform and its potential to "redefine standards" in endocrine and metabolic disease treatment.
The firm initiated coverage on MBX Biosciences with an outperform rating and a $38 price target.
Price: 12.40, Change: -1.00, Percent Change: -7.46
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.